Compare OSW & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSW | SRPT |
|---|---|---|
| Founded | 2017 | 1980 |
| Country | Bahamas | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2019 | 2000 |
| Metric | OSW | SRPT |
|---|---|---|
| Price | $27.62 | $16.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 29 |
| Target Price | ★ $27.00 | $25.85 |
| AVG Volume (30 Days) | 663.1K | ★ 2.8M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.21 | ★ 2.88 |
| Revenue | $961,001,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $7.49 | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | $133.81 | ★ $5.99 |
| Revenue Growth | 7.37 | ★ 15.58 |
| 52 Week Low | $19.06 | $10.42 |
| 52 Week High | $28.24 | $25.32 |
| Indicator | OSW | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 69.83 | 47.97 |
| Support Level | $19.70 | $16.37 |
| Resistance Level | N/A | $18.16 |
| Average True Range (ATR) | 0.93 | 0.76 |
| MACD | 0.35 | 0.31 |
| Stochastic Oscillator | 79.02 | 61.15 |
OneSpaWorld Holdings Ltd is an operator of health and wellness centers onboard cruise ships and an operator of health and wellness centers at destination resorts all over the world. It offers a suite of premium health, fitness, beauty, and wellness services and products. The services provided by the company include body, salon, and skin care services and products, fitness classes and personal fitness training and pain management, detoxifying programs, and comprehensive body composition analyses among others. The company has only one single segment of Maritime and Destination Resorts.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.